Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State

Competing Interest Statement

A.L.G. reports contract testing from Abbott Laboratories and research support from Gilead and Merck, outside of the described work.

Funding Statement

This work is supported by the National Institutes of Health [ORIP grant S10OD028685 to Scientific Computing at Fred Hutch, and UW-Fred Hutch CFAR AI027757 to P.R.].

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This work was approved by the University of Washington Institutional Review Board.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes